Pharmacogenetics in the management of coumarin anticoagulant therapy: the way forward or an expensive diversion?
- PMID: 16231978
- PMCID: PMC1261512
- DOI: 10.1371/journal.pmed.0020342
Pharmacogenetics in the management of coumarin anticoagulant therapy: the way forward or an expensive diversion?
Abstract
Greaves discusses a new study in PLoS Medicine that takes us closer to being able to adopt a pharmacogenetic approach to reduce bleeding risk from coumarin therapy.
Conflict of interest statement
Comment on
-
A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk.PLoS Med. 2005 Oct;2(10):e312. doi: 10.1371/journal.pmed.0020312. Epub 2005 Oct 11. PLoS Med. 2005. PMID: 16201835 Free PMC article.
References
-
- Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, et al. Identification of the gene for vitamin K epoxide reductase. Nature. 2004;427:541–544. - PubMed
-
- Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, et al. Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet. 1996;348:423–428. - PubMed
-
- Panneerselvam S, Baglin C, Lefort W, Baglin T. Analysis of risk factors for over-anticoagulation in patients receiving long-term warfarin. Brit J Haematol. 1998;103:422–424. - PubMed
-
- Lubetsky A, Dekel-Stem E, Chetrit A, Lubin F, Halkin H. Vitamin K intake and sensitivity to warfarin in patients consuming regular diets. Thrombos Haemostas. 1999;81:396–399. - PubMed
-
- Yu HC, Chan TY, Critchley JA, Woo KS. Factors determining the maintenance dose of warfarin in Chinese patients. QJM. 1996;89:127–135. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
